Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOCIDYS: Tocilizumab for fibrous dysplasia of bone refractory to bisphosphonates
2010-024282-41Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in fibrous dysplasia comparing Tocilizumab with Placebo (2 arms). Primary endpoint: Serum CTX change at 6 months. Started Aug 2012; status: completed.
02
Drugs
tocilizumab
03
Conditions
fibrous dysplasia
Beyond the preview
Go deeper on 2010-024282-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024282-41.